Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/30/19
End: 08/11/22
Due: 08/11/23
Phase: N/A
Priority: Normal
Start: 04/30/22
End: 05/11/22
Due: 05/11/23
Phase: N/A
Priority: Normal
Start: 12/01/22
End: 05/31/24
Due: 05/31/25
Phase: N/A
Priority: Normal
Start: 11/29/22
End: 05/30/23
Due: 05/30/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of GFH018 in Patients With Advanced Solid Tumors | NCT05051241 | Zhejiang Genfleet Therapeutics Co., Ltd. | user2@example.com | None | 2019-08-30 | 2022-08-11 | 2023-08-11 | - | - | 2025-07-14 |
| A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors | NCT05165849 | Zhejiang Genfleet Therapeutics Co., Ltd. | user2@example.com | None | 2022-04-30 | 2022-05-11 | 2023-05-11 | - | - | 2025-07-14 |
| A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC) | NCT05618691 | Zhejiang Genfleet Therapeutics Co., Ltd. | user2@example.com | None | 2022-12-01 | 2024-05-31 | 2025-05-31 | - | - | 2025-07-14 |
| A Phase I Study of GFH312 in Healthy Chinese Subjects | NCT05991362 | Zhejiang Genfleet Therapeutics Co., Ltd. | user2@example.com | None | 2022-11-29 | 2023-05-30 | 2024-05-30 | - | - | 2025-07-14 |